Table 1_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 1_The trajectory of intrinsic capacity and its related factors among elderly Chinese patients with cardiovascular disease: a prospective cohort study.docx by Yanyin Cui (21428879)

“…</p>Results<p>The GBTM model identified three categories of IC trajectories among elderly patients with CVD: the low-decreased group (n=162, 23.11%), the high-increased group (n=196, 27.96%), and the medium-stable group (n=343, 48.93%). …”

Supplementary Material for: Endoscopic Anti-reflux Mucosal Interventions for Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Efficacy, Safety, and Compara... by figshare admin karger (2628495)

“…Results: Technical success was 100%, with a mean procedure time of 42.09 minutes. ARMIs significantly reduced the proportion of patients using PPI (RR=2.22-3.06; <3–24 months; P≤0.001) and improved GERD-Q, GERD-HRQL, and DeMeester scores through 36 months (P<0.05). …”

Supplementary file 1_Burden of ageing spectrum of diseases in China, 1990–2021: a systematic analysis of global burden of disease study 2021.pdf by Li Yang (6520)

“…Background<p>Population aging represents a pressing challenge for China, given its vast population and the growing proportion of adults aged 65 years and older. …”

Four-site distal paravertebral blocks improve physiologic indicators of analgesia in the immediate postoperative period as opposed to a three-site distal paravertebral block by Kelley Varner (16899048)

“…Clinical Relevance: Adding a fourth injection site at L3 decreases physiologic indicators of postoperative discomfort.…”

Table 2_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

Table 3_Efgartigimod for the treatment of immune checkpoint inhibitor-associated myocarditis complicated with impending crisis state of myasthenia gravis: a case report.docx by Mingjia Lu (21593324)

“…Treatment with efgartigimod (10 mg/kg) significantly improved myasthenic symptoms, with Myasthenia Gravis–Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores decreasing from 11 to 5 and 26 to 11, respectively. …”

<i>ADH7, FABP5, ALDH1A1, CRABP-2, PPARγ</i> and <i>VEGFA</i> mRNA and ADH7, FABP5, CRABP-2, PPARγ and VEGFA protein levels in limbal stromal cells (LSCs) and aniridia limbal stroma... by Shuailin Li (11907158)

“…<i>ADH7, FABP5</i> and <i>VEGFA</i> mRNA levels were significantly higher in AN-LSCs, than in LSCs (p ≤ 0.037) while ADH7 protein level was significantly lower in AN-LSCs, than in LSCs (p = 0.022) <b>(A, B, D, O)</b>. …”

Table 1_A real-world study of polyenyl phosphatidylcholine in the management of patients with metabolic dysfunction-associated fatty liver disease in China clinical practice.docx by Yi Pan (68170)

“…In the PPC group, baseline alanine transaminase (ALT) levels decreased at 12- and 24-weeks compared to those of the control group, but results were not significant. …”

Video 1_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 by Xin Fei (20466992)

“…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”

Video 2_Anlotinib combined with tislelizumab in the treatment of primary small cell neuroendocrine carcinoma of the prostate: a case report and literature review.mp4 by Xin Fei (20466992)

“…The patient was then administered a combination of anlotinib and tislelizumab. After treatment, the patient’s symptoms were controlled, tumor marker levels decreased, and imaging showed significant improvement. …”

Table 1_A cohort-based assessment of drug use trends during the COVID-19 pandemic: relationship with mood and sociodemographic factors in Brazil.docx by Nubia Heidrich (14079741)

“…<p>The COVID-19 pandemic has brought significant challenges, including severe psychological consequences, especially for vulnerable individuals, such as those with substance use disorders. …”

Image 3_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Image 2_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Image 4_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Image 1_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.jpeg by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Table 1_Global trends of early-onset Parkinson’s disease from 1990 to 2021, and projections until to 2030: a systematic analysis of the global burden of disease study 2021.docx by Bingtao Hu (16784702)

“…The geographical disparities at regional and national level were evident. Significant disparities in EOPD burden by SDI were observed, exhibiting a worsening inequality over time. …”

Table 1_Baicalein from Scutellaria baicalensis mitigates oxidative stress through the IIS pathway in a C. elegans model of ulcerative colitis.docx by Wei Wang (17594)

“…Introduction<p>Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease with limited therapeutic options. …”

Image 1_Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.tiff by José De Jesus Bravo-Silva (21898316)

“…Melatonin, a hormone with antioxidant and immunomodulatory properties, has previously been shown to inhibit Japanese encephalitis virus (JEV) replication through RhoA pathway modulation.…”

Image 3_Pharmacological inhibition of the RhoA pathway by melatonin reduces viral replication and proinflammatory response against ZIKV and DENV-4 neuroinfections.tiff by José De Jesus Bravo-Silva (21898316)

“…Melatonin, a hormone with antioxidant and immunomodulatory properties, has previously been shown to inhibit Japanese encephalitis virus (JEV) replication through RhoA pathway modulation.…”